Whether anti-OX40 functions via Treg cell suppression, deletion, or both, treatment with these agonists should diminish the inhibitory effects mediated by Treg cells and thereby promote anti-tumor CD8 T cell responses necessary to maintain long-term anti-tumor immune responses. The gene discussed is CD8A; the disease is neoplasm.